Eli Lilly expects to launch the drug for OSA at the beginning ... The index is used to evaluate the severity of obstructive ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

An estimated 39 million American adults suffer from obstructive sleep apnea, a condition in which the upper airway is blocked while sleeping.

Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication ...